Lunsumio VELO™ – BiotechReality – Information Intelligence System for Biopharma

Roche announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lunsumio VELO™ (mosunetuzumab), a subcutaneous (SC) formulation for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The treatment is indicated for those who have received at least two prior lines of systemic therapy. This milestone marks a significant shift in the delivery of care for follicular lymphoma, a chronic form of non-Hodgkin lymphoma. By moving from a traditional intravenous (IV) infusion to a subcutaneous injection, the administration time is slashed from several hours to approximately one minute. A New Standard for Patient Convenience Follicular lymphoma is characterized by a cycle of remissions and relapses, often requiring lifelong management. Traditional treatments can be burdensome, requiring patients to spend half a day in a clinic for infusions. With this FDA approval, treatment can now be administered in just one minute, which significantly reduces the time patients spend in the clinic and helps to align care with their individual needs and preferences. Levi Garraway Key Clinical Advantages Fixed Duration: Treatment is given for a set period (as short as six months), unlike "treat-to-progression" therapies that continue indefinitely. Outpatient Access: Designed for use in community practice settings, increasing accessibility for patients outside of major academic hospitals. Rapid Delivery: Reduced from 2–4 hours (IV) to ~1 minute (SC). Read More: European Commission Approves Roche’s Subcutaneous Lunsumio for Relapsed or Refractory Follicular Lymphoma Efficacy and Safety Profile The approval is based on data from the Phase I/II GO29781 study, which evaluated Lunsumio VELO in patients with third-line or later (3L+) follicular lymphoma. The data demonstrated that the subcutaneous formulation maintained the high efficacy standards set by the original IV version. MetricOutcome (95% CI)Objective Response Rate (ORR)75% (64–83%)Complete Response Rate (CR)59% (48–69%)Median Duration of Response22.4 months Safety Considerations The study reported a manageable safety profile. The most common adverse reactions (≥20%) included injection site reactions, fatigue, rash, and cytokine release syndrome (CRS). CRS Incidence: 30% of patients experienced CRS. Severity: Most events were low-grade (Grade 1–2: 28%; Grade 3: 2.1%). Resolution: CRS events typically occurred during the first cycle and were resolved within a median of two days. The Road Ahead: Expanding the Portfolio While this accelerated approval is a major win for patients with advanced disease, Roche is already looking toward earlier lines of treatment. Ongoing Phase III trials include: SUNMO Study: Investigating Lunsumio VELO + Polivy® for second-line large B-cell lymphoma. MorningLyte Study: Investigating Lunsumio VELO + lenalidomide for previously untreated follicular lymphoma. As part of the accelerated approval pathway, Roche may be required to conduct confirmatory trials to verify the long-term clinical benefit of this regimen. Information: Roche Last Modified:

Tag: Lunsumio VELO™

FDA Grants Accelerated Approval to Roche’s One-Minute Lymphoma Injection, Lunsumio VELO™

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment